# Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients

> **NCT01318096** · NA · UNKNOWN · sponsor: **Yunnan AIDS Care Center** · enrollment: 60 (estimated)

## Conditions studied

- HBV Coinfection
- HIV Infections

## Interventions

- **DRUG:** raltegravir and tenofovir and lamivudine
- **DRUG:** efavirenz+tenofovir+lamivudine

## Key facts

- **NCT ID:** NCT01318096
- **Lead sponsor:** Yunnan AIDS Care Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-03
- **Primary completion:** 2012-07
- **Final completion:** 2013-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01318096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01318096, "Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01318096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*